Why Disc Medicine (IRON) Is Up 28.7% After Securing FDA Priority Review for Bitopertin Accelerated Approval [Yahoo! Finance]
Disc Medicine, Inc. (IRON)
Company Research
Source: Yahoo! Finance
protoporphyria and submitted a New Drug Application seeking accelerated approval for patients aged 12 and older. This regulatory milestone allows Disc Medicine potential access to a dramatically expedited 1-2 month review timeline for a therapy aimed at a rare, debilitating disease with limited treatment options. We'll explore how the FDA's accelerated review program for bitopertin could reshape Disc Medicine's investment narrative and competitive positioning. AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. What Is Disc Medicine's Investment Narrative? For anyone considering Disc Medicine today, the central thesis hinges on the approval and successful commercialization of bitopertin, which targets a rare and severely debilitating disease. The company's receipt of a Commissioner's National Priority Voucher from the
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Truist Financial Corporation from $86.00 to $114.00. They now have a "buy" rating on the stock.MarketBeat
- What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]Yahoo! Finance
- Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $125.00 price target on the stock.MarketBeat
IRON
Earnings
- 11/6/25 - Miss
IRON
Sec Filings
- 11/13/25 - Form 4
- 11/12/25 - Form 144
- 11/6/25 - Form 10-Q
- IRON's page on the SEC website